Overdue Revision Of EU Cancer Screening Would Benefit Medtech Industry As Incidence Skyrockets

Council of the EU recommendations on cancer screening have not changed in some 20 years, yet the increase in cancer rates is alarming. Industry associations, COCIR and MedTech Europe have come out in support of the European Commission’s push for a revision.

Daria Artemenko/Alamy Stock Photo — (Daria Artemenko / Alamy Stock Ph/Alamy Stock Photo)

European medtech industry associations COCIR and MedTech Europe are urging the Council of the EU to adopt the European Commission’s proposal to update the 2003 Council Recommendation on the screening of breast, cervical and colorectal cancers and extend it to lung, prostate and - to some extent - gastric cancers.

The commission proposal emphasizes the benefits of cancer detection through high-quality smart screening, would expand the number of different types...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

11 Jul 2025

• By Amanda Maxwell

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

10 Jul 2025

• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

10 Jul 2025

• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

09 Jul 2025

• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.